Home | All trials

[RDF data]
Trial NCT00000428

Resource URI: http://static.linkedct.org/resource/trials/NCT00000428
linkedct:arm_group <http://static.linkedct.org/resource/arm_group/8637>
linkedct:brief_title Combining N-of-1 Trials to Assess Fibromyalgia Treatments
linkedct:condition <http://static.linkedct.org/resource/condition/4899>
linkedct:criteria Inclusion Criteria: - Patients who meet fibromyalgia criteria as defined by the American College of Rheumatology - No systemic illness (current or past) or other contraindications to taking study medications (e.g. known hypersensitivity) - Age 18-60 - Patient willingness, and physician agreement, to discontinue CNS medications/NSAIDs/analgesics for 1 week prior to starting their trial - Patient informed consent and agreement to participate in an N-of-1 trial Exclusion Criteria: - Patients who are currently pregnant or who plan to become pregnant during the study period - Patients with any contraindications to using either amitriptyline or fluoxetine
linkedct:description This study will use the combined N-of-1 method to compare the effectiveness of the combination therapy amitriptyline and fluoxetine (AM+FL) versus amitriptyline (AM) alone in patients with fibromyalgia (FM). It will also compare community-based and center-based trial results. We will ask community-based, board-certified rheumatologists to participate as investigators and we will also carry out a center-based study (at Newton-Wellesley Hospital). Physicians will ask patients meeting eligibility criteria to participate in this study and undergo an N-of-1 trial. Each N-of-1 trial will consist of three paired crossover periods (each 6-weeks long) during which the patient will receive either AM + placebo (placebo every morning and AM 25 mg at night) or combination treatment AM+FL (FL 20 mg in the morning and AM 25 mg at night). The dispensing pharmacy will carry out paired randomization. We will assess patient evaluations and outcome measures at baseline prior to trial, at the end of each treatment period, and 3 months after completion of the N-of-1 trial. In addition, at baseline, we will obtain demographic information, an electrocardiogram, and baseline blood tests. We may ask patients to have additional blood tests at the period evaluations. We will also do a pregnancy test for all women of child-bearing age enrolling in the study. The main study outcome measure will be the Fibromyalgia Impact Questionnaire (FIQ). Additional measures will include the Visual Analog Scales (VAS) for pain, sleep, global well-being; Physician VAS for global well-being; and tender-point score. We will analyze the results of the N-of-1 trials in two ways: (1) using only the individual patient's results (classic one-sided t-test) and (2) using the patient's results in combination with the results of other patients who underwent similar trials (the combined N-of-1 approach). To obtain the latter information, we will include each patient's results for the collective analysis. We will provide these results back to the physicians and will record the final treatment decisions the physicians reach with their patients. In addition, we will ask both physicians and patients to comment on their participation in an N-of-1 trial and this research process. Followup of patients 3 months after completion of their N-of-1 trial will include determining current medication and a current outcome assessment. Investigators will record all adverse drug reactions and patients withdrawn from studies. They will also record the reason for withdrawal for all patients choosing to withdraw. We will include results from patients who drop out due to reasons other than drug reactions in the combined N-of-1 analyses if completed period pair results are available. An independent safety officer will review all withdrawals. Results of individual patient trials will be confidential; however, we will combine these results (after removal of patient identifiers) with the results of other patients, and will publish the overall results of this study. We will maintain the connection of results to patient identifiers only to enable us to provide results to individual investigators and their patients.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 60 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:end_date March 2004
linkedct:enrollment 58 (xsd:int)
linkedct:firstreceived_date January 18, 2000
linkedct:has_dmc Yes
linkedct:id NCT00000428
linkedct:intervention <http://static.linkedct.org/resource/intervention/31696>
linkedct:intervention <http://static.linkedct.org/resource/intervention/31697>
rdfs:label Trial NCT00000428
linkedct:lastchanged_date March 5, 2008
linkedct:lead_sponsor_agency National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
linkedct:location <http://static.linkedct.org/resource/location/147079>
linkedct:location <http://static.linkedct.org/resource/location/147219>
linkedct:location <http://static.linkedct.org/resource/location/148118>
linkedct:location <http://static.linkedct.org/resource/location/148129>
linkedct:location <http://static.linkedct.org/resource/location/148153>
linkedct:location <http://static.linkedct.org/resource/location/148342>
linkedct:location <http://static.linkedct.org/resource/location/148532>
linkedct:nct_id NCT00000428
linkedct:number_of_arms 1 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Combining N-of-1 Trials to Assess Fibromyalgia Therapies
linkedct:org_study_id R01 AR45416
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/13340>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000428>
linkedct:phase Phase 4
linkedct:primary_completion_date March 2004
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/54961>
linkedct:reference <http://static.linkedct.org/resource/reference/38786>
linkedct:reference <http://static.linkedct.org/resource/reference/40111>
linkedct:reference <http://static.linkedct.org/resource/reference/40976>
linkedct:reference <http://static.linkedct.org/resource/reference/51056>
linkedct:reference <http://static.linkedct.org/resource/reference/52379>
linkedct:results_reference <http://static.linkedct.org/resource/results_reference/6500>
linkedct:secondary_id NIAMS-038
linkedct:source National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
linkedct:start_date September 2000
linkedct:study_design Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Crossover Assignment, Efficacy Study
linkedct:study_type Interventional
linkedct:summary This study will compare the effectiveness of combination therapy with the drugs amitriptyline and fluoxetine (AM+FL) and amitriptyline (AM) alone in the treatment of people with fibromyalgia. Doctors will treat each study participant with both AM + FL and AM alone for 6 weeks at a time. The study uses a method that combines results from treatment of individual patients to assess overall treatment effectiveness and help individual patients and their physicians with their treatment decisions. This study will also help compare the results of community-based studies (studies involving private doctors) and studies based at clinical research centers.
rdf:type linkedct:trials
linkedct:verification_date March 2008